Mode
Text Size
Log in / Sign up

ANCA-Associated Vasculitis

Part of Vasculitis

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for ANCA-Associated Vasculitis

2 trials tracked for ANCA-Associated Vasculitis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 955 citations.

2Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 1
  1. Phase 3 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Completed · 955 cited
  2. Phase 2 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Vasculitis

Related studies from across the Vasculitis family.

Questions about ANCA-Associated Vasculitis

Are patients with granulomatosis with polyangiitis at higher risk for cardiovascular events?

Patients with granulomatosis with polyangiitis face a significantly higher risk of cardiovascular events like heart attacks and strokes compared to the general population.

Full answer →
Which type of ANCA-associated vasculitis has the worst prognosis for patients?

Microscopic polyangiitis (MPA) has the worst long-term prognosis among the types of ANCA-associated vasculitis, with lower five-year survival rates compared to other subtypes.

Full answer →
Does having ANCA-associated vasculitis increase my risk of heart problems and death?

Having ANCA-associated vasculitis significantly increases your risk of heart attacks, strokes, blood clots, and death compared to people without the disease.

Full answer →